Changqi Biotech – Empowering veterinarians and pet owners with lab-grade accuracy and 

speed through advanced isothermal amplification technology.

Changqi Biotech was founded by elite scientists from Harvard University and Shanghai Jiao Tong University. Since official establishment in 2024, we have dedicated ourselves to revolutionizing molecular diagnostics. We developed China's first fully automated, ultra-multiplex microfluidic system based on isothermal amplification. Our mission is to act as a "Home Veterinary Guardian," making lab-grade testing accessible and fast (5-15 mins) for everyone.

Elite R&D: Led by Harvard & SJTU researchers

Rapid Tech: Results in 5-15 minutes.

Vertical Supply: In-house reagents & device production.

Closed-Loop: Partnered with JD Health & New Ruipeng.

Driven by a multidisciplinary team of experts since 2020, we are dedicated to overcoming the toughest challenges in molecular diagnostics.

Academic Leadership

Spearheaded by postdoctoral researchers from Harvard University and doctoral supervisors from Shanghai Jiao Tong University, ensuring top-tier scientific rigor.

Multidisciplinary Synergy

Pioneering Innovation

A unique fusion of clinical medicine, molecular biology, and microfluidic engineering. We bridge the gap between complex lab protocols and simple home use.

We developed China's first fully automated isothermal microfluidic system, filling a critical market gap with 100% proprietary intellectual property.

Officially established Changqi Biotech (Suzhou) to lead the commercialization of our tech.

Oct 2024: Product Launch

The first-generation Mini series isothermal nucleic acid amplification instrument was launched, enabling on-site results within 5–15 minutes.

June 2024: Obtained CE certification

The core product obtained EU CE certification, gaining qualification for entry into international markets.

Oct 2025: High-Speed Rail Alliance

Partnered with China High-Speed Rail to provide exclusive rapid testing for pet transport safety.

Nov 2025: The test results were highly consistent with the qPCR gold standard

Through technical comparison by the Shanghai Veterinary Research Institute of the Chinese Academy of Agricultural Sciences, the test results were highly consistent with the qPCR gold standard; simultaneously, 6 utility model patents received national authorization.

2026: Future Expansion

Plan to launch early tumor and cardiovascular gene screening products for chronic disease care.

From rigorous R&D to market leadership. Trace our path in redefining molecular diagnostics.

June 2024: Official Establishment

Unlike assemblers, Changqi Biotech produces its own core enzymes, reagents, and instruments. This vertical integration ensures maximum cost efficiency, supply stability, and consistent quality for our global partners.

In-House Raw Materials: 

Proprietary synthesis of core enzymes and reagents.

Automated Assembly: 

High-volume automated lines for chips and devices.

Strict Quality Control: 

Rigorous testing protocols at every production stage.

Cost Advantage:

Direct-from-factory pricing with no middleman markups.